Treatment of prostate cancer cell lines with Androgen Receptor and Receptor Tyrosine Kinase inhibitors
RNA-seq (gene expression) · human · 246 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Prostate cancerThis series is part of our curated briefing on it.
- Samples
- 246 samples: 116 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibitionThe Journal of clinical investigation · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE222196_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA918580 and SRA study SRP415944. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 241 samples.
How we read this: 116 replicated groups read from 246 sample titles; they account for 241 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM6917561 LNCap, DAC, 0 days, rep2 LNCap, DAC, 0 days,
- GSM6917562 LNCap, DAC, 1 day, rep2 LNCap, DAC, 1 day,
- GSM6917563 LNCap, DAC, 3 days, rep2 LNCap, DAC, 3 days,
- GSM6917564 LNCap, DAC, 5 days, rep2 LNCap, DAC, 5 days,
- GSM6917565 LNCap, NER, 0 days, rep1 LNCap, NER, 0 days,
- GSM6917566 LNCap, NER, 1 day, rep1 LNCap, NER, 1 day,
- GSM6917567 LNCap, NER, 3 days, rep1 LNCap, NER, 3 days,
- GSM6917568 LNCap, NER, 5 days, rep1 LNCap, NER, 5 days,
- GSM6917569 LNCap, AFA, 0 days, rep1 LNCap, AFA, 0 days,
- GSM6917570 LNCap, SUN, 1 day, rep1 LNCap, SUN, 1 day,
- GSM6917571 LNCap, AFA, 1 day, rep1 LNCap, AFA, 1 day,
- GSM6917572 LNCap, AFA, 3 days, rep1 LNCap, AFA, 3 days,
- GSM6917573 LNCap, AFA, 5 days, rep1 LNCap, AFA, 5 days,
- GSM6917574 LNCap, LAP, 0 days, rep2 LNCap, LAP, 0 days,
- GSM6917575 LNCap, LAP, 1 day, rep2 LNCap, LAP, 1 day,
- GSM6917576 LNCap, LAP, 3 days, rep2 LNCap, LAP, 3 days,
- GSM6917577 LNCap, LAP, 5 days, rep2
- GSM6917578 LNCap, SUN, 0 days, rep1 LNCap, SUN, 0 days,
- GSM6917579 22Rv1, DAC, 0 days, rep1 22Rv1, DAC, 0 days,
- GSM6917580 22Rv1, DAC, 1 day, rep1 22Rv1, DAC, 1 day,
- GSM6917581 22Rv1, DAC, 3 days, rep1 22Rv1, DAC, 3 days,
- GSM6917582 22Rv1, DAC, 5 days, rep1 22Rv1, DAC, 5 days,
- GSM6917583 LNCap, VAN, 0 days, rep1 LNCap, VAN, 0 days,
- GSM6917584 LNCap, VAN, 1 day, rep1 LNCap, VAN, 1 day,
- GSM6917585 LNCap, VAN, 3 days, rep1 LNCap, VAN, 3 days,
- GSM6917586 LNCap, VAN, 5 days, rep1 LNCap, VAN, 5 days,
- GSM6917587 22Rv1, GEF, 0 days, rep1 22Rv1, GEF, 0 days,
- GSM6917588 22Rv1, GEF, 1 day, rep1 22Rv1, GEF, 1 day,
- GSM6917589 22Rv1, GEF, 3 days, rep1 22Rv1, GEF, 3 days,
- GSM6917590 22Rv1, GEF, 5 days, rep1 22Rv1, GEF, 5 days,
- GSM6917591 22Rv1, ENZ, 0 days, rep1 22Rv1, ENZ, 0 days,
- GSM6917592 LNCap, AFA, 1 day, rep2 LNCap, AFA, 1 day,
- GSM6917593 LNCap, AFA, 3 days, rep2 LNCap, AFA, 3 days,
- GSM6917594 LNCap, AFA, 5 days, rep2 LNCap, AFA, 5 days,
- GSM6917595 22Rv1, ENZ, 1 day, rep1 22Rv1, ENZ, 1 day,
- GSM6917596 22Rv1, ENZ, 3 days, rep1 22Rv1, ENZ, 3 days,
- GSM6917597 22Rv1, ENZ, 5 days, rep1 22Rv1, ENZ, 5 days,
- GSM6917598 22Rv1, LAP, 0 days, rep2 22Rv1, LAP, 0 days,
- GSM6917599 22Rv1, LAP, 1 day, rep2 22Rv1, LAP, 1 day,
- GSM6917600 22Rv1, LAP, 3 days, rep2 22Rv1, LAP, 3 days,
+ 206 more — browse all 246 samples with per-sample file links →
- GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing · shares treatment, prostate
- GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing · shares prostate
- GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing · shares prostate
- GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing · shares prostate
- GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing
- GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
- GSE339459 5β-Dihydrotestosterone and mutant androgen receptor vulnerability in prostate cancer 30 samples shares prostate, androgen, receptor
- GSE245851 Transcriptomic analysis of human gastric cancer cell lines following T-DXd treatment 15 samples shares treatment, lines
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.